Cited 1 times in
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 손주혁 | - |
dc.date.accessioned | 2024-03-22T06:16:10Z | - |
dc.date.available | 2024-03-22T06:16:10Z | - |
dc.date.issued | 2023-03 | - |
dc.identifier.issn | 0959-8049 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/198490 | - |
dc.description.abstract | Background: Dual anti-HER2-targeted therapy in breast cancer (BC) significantly increased the rate of pathological complete response (pCR) compared to single blockade when added to chemotherapy. However, limited data exist on the long-term impact on survival of the additional increase in pCR. Methods: Neoadjuvant lapatinib and/or trastuzumab treatment optimisation (NCT00553358) is an international, randomised, open-label, phase III study investigating the addition of lapatinib to chemotherapy plus trastuzumab in HER2-positive early BC. Ten-year event-free survival (EFS), overall survival (OS) and safety were assessed on intention-to-treat population. The association between pCR and EFS or OS was investigated in landmark population. Results: A total of 455 patients were randomised to receive lapatinib (154), trastuzumab (149) or the combination (152). Ten-year EFS estimates were 63% (95% confidence interval [CI], 54%–71%) in the lapatinib group, 64% (95% CI, 55%–72%) in the trastuzumab group and 67% (95% CI, 58%–74%) in the combination group. Ten-year OS rates were 76% (95% CI, 67%–83%), 75% (95% CI, 66%–82%) and 80% (95% CI, 73%–86%) in the lapatinib, trastuzumab and combination groups, respectively. Women who achieved a pCR had improved EFS (hazard ratio 0.48, 95% CI, 0.31–0.73) and OS (hazard ratio 0.37, 95% CI, 0.20–0.63) compared with those who did not. The numerical difference in survival according to pCR status was greater in women treated with the combination and those with hormone-receptor-negative tumours. There were no new or long-term safety concerns. Conclusions: Patients with HER2-positive BC showed a durable survival benefit of neoadjuvant anti-HER2, irrespective of treatment arm. Patients who achieve pCR have significantly better outcomes than patients without pCR. © 2022 Elsevier Ltd | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Elsevier Science Ltd | - |
dc.relation.isPartOf | EUROPEAN JOURNAL OF CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / therapeutic use | - |
dc.subject.MESH | Breast Neoplasms* / pathology | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lapatinib / therapeutic use | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Neoadjuvant Therapy | - |
dc.subject.MESH | Receptor, ErbB-2 | - |
dc.subject.MESH | Trastuzumab / adverse effects | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Paolo Nuciforo | - |
dc.contributor.googleauthor | John Townend | - |
dc.contributor.googleauthor | Martine J Piccart | - |
dc.contributor.googleauthor | Shona Fielding | - |
dc.contributor.googleauthor | Panagiota Gkolfi | - |
dc.contributor.googleauthor | Sarra El-Abed | - |
dc.contributor.googleauthor | Evandro de Azambuja | - |
dc.contributor.googleauthor | Gustavo Werutsky | - |
dc.contributor.googleauthor | Judith Bliss | - |
dc.contributor.googleauthor | Volker Moebus | - |
dc.contributor.googleauthor | Marco Colleoni | - |
dc.contributor.googleauthor | Alvaro Moreno Aspitia | - |
dc.contributor.googleauthor | Henry Gomez | - |
dc.contributor.googleauthor | Andrea Gombos | - |
dc.contributor.googleauthor | Maria A Coccia-Portugal | - |
dc.contributor.googleauthor | Ling-Ming Tseng | - |
dc.contributor.googleauthor | Georg Kunz | - |
dc.contributor.googleauthor | Guillermo Lerzo | - |
dc.contributor.googleauthor | Joohyuk Sohn | - |
dc.contributor.googleauthor | Vladimir Semiglazov | - |
dc.contributor.googleauthor | Cristina Saura | - |
dc.contributor.googleauthor | Judith Kroep | - |
dc.contributor.googleauthor | Antonella Ferro | - |
dc.contributor.googleauthor | David Cameron | - |
dc.contributor.googleauthor | Richard Gelber | - |
dc.contributor.googleauthor | Jens Huober | - |
dc.contributor.googleauthor | Serena Di Cosimo | - |
dc.identifier.doi | 10.1016/j.ejca.2022.12.020 | - |
dc.contributor.localId | A01995 | - |
dc.relation.journalcode | J00809 | - |
dc.identifier.eissn | 1879-0852 | - |
dc.identifier.pmid | 36641898 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0959804922018317 | - |
dc.subject.keyword | Breast cancer | - |
dc.subject.keyword | Dual anti-HER2 blockade | - |
dc.subject.keyword | HER2-Positive | - |
dc.subject.keyword | Long-term survival | - |
dc.subject.keyword | Neoadjuvant | - |
dc.subject.keyword | Pathological complete response | - |
dc.contributor.alternativeName | Sohn, Joo Hyuk | - |
dc.contributor.affiliatedAuthor | 손주혁 | - |
dc.citation.volume | 181 | - |
dc.citation.startPage | 92 | - |
dc.citation.endPage | 101 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF CANCER, Vol.181 : 92-101, 2023-03 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.